Sobi Names Trista Morrison Vice President of Communications in North America

Waltham, Mass., Aug. 16, 2017— Sobi, a leading integrated global biopharmaceutical company dedicated to rare and difficult-to-treat diseases,...

Read more

The board of directors exercises authorization for repurchase of shares to secure the company’s commitments under incentive programme

The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 4 May 2017 resolved – for the purpose of ensuring that the company can fulfil its...

Read more

Sobi™ publishes its report for the second quarter 2017

Read more

Sobi and Bioverativ highlight commitment to improving care for people with haemophilia at ISTH 2017 congress

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI)  and Bioverativ Inc. (NASDAQ: BIVV) today announces that new data from their extended half-life...

Read more

Invitation – Presentation of Sobi’s Q2 2017 results

On 19 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2017.

Financial analysts and media...

Read more

FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA

Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the...

Read more

Xiapex® gets recommendation to be made available on National Health Service in England

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that for the first time people in England with the disabling hand condition Dupuytren’s...

Read more

EMA approves the potential to dose every 14 days or longer in updated dosing regimen for Alprolix®

Swedish Orphan Biovitrum AB (publ) (Sobi™) has received approval from the European Medicines Agency (EMA) to update the dosing information for...

Read more

Chief Operating Officer Alan Raffensperger to leave Sobi™

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the company and Alan Raffensperger, Chief Operating Officer (COO), have come to the...

Read more

Sobi™ keeps the Partner Products business area as an integral part of the company

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Partner Products business area will remain an integral part of Sobi’s business...

Read more

Archive